File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/RLU.0000000000004235
- Scopus: eid_2-s2.0-85135599157
- PMID: 35485851
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis
Title | The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis |
---|---|
Authors | |
Keywords | 68Ga DOTA management neuroendocrine tumors peptide receptor radionuclide therapy PET/CT |
Issue Date | 1-Sep-2022 |
Publisher | Lippincott, Williams & Wilkins |
Citation | Clinical Nuclear Medicine, 2022, v. 47, n. 9, p. 781-793 How to Cite? |
Abstract | Purpose The aim of this study was to identify and evaluate the role of 68Ga-DOTA-somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on the ability of PET/CT to impact clinical management and predict peptide receptor radionuclide therapy (PRRT) response. Patients and Methods A systematic literature search of articles up to December 2021 was performed using PubMed and Scopus. Eligible studies included ≥10 patients with confirmed or suspected NETs who had undergone pretreatment staging 68Ga-DOTA-SSA PET/CT. A meta-analysis using the random-effects model was conducted to determine the overall change in management after PET/CT, whereas PET/CT-derived parameters that correlated with PRRT outcome were summarized from studies that assessed its predictive capabilities. Results A total of 39 studies were included in this systemic review, of which 2266 patients from 24 studies were included for meta-analysis. We showed that PET/CT resulted in a change in clinical management in 36% (95% confidence interval, 31%-41%; range, 3%-66%) of patients. Fifteen studies consisting of 618 patients examined the prognostic ability of 68Ga-DOTA-SSA PET/CT for PRRT. Of those, 8 studies identified a higher pretreatment SUV to favor PRRT, and 4 identified PET-based radiomic features for somatostatin receptor heterogeneity to be predictive of PRRT response. Conclusions Along with its diagnostic abilities, 68Ga-DOTA-SSA PET/CT can impact treatment decision-making and may predict PRRT response in patients with NETs. More robust studies should be conducted to better elucidate the prognostic role of somatostatin receptor PET/CT in optimizing treatment for clinical outcome. |
Persistent Identifier | http://hdl.handle.net/10722/344907 |
ISSN | 2023 Impact Factor: 9.6 2023 SCImago Journal Rankings: 0.571 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Osher Ngo Yung | - |
dc.contributor.author | Tan, Kel Vin | - |
dc.contributor.author | Tripathi, Vrijesh | - |
dc.contributor.author | Yuan, Hui | - |
dc.contributor.author | Chan, Wendy Wing Lok | - |
dc.contributor.author | Chiu, Keith Wan Hang | - |
dc.date.accessioned | 2024-08-13T06:51:05Z | - |
dc.date.available | 2024-08-13T06:51:05Z | - |
dc.date.issued | 2022-09-01 | - |
dc.identifier.citation | Clinical Nuclear Medicine, 2022, v. 47, n. 9, p. 781-793 | - |
dc.identifier.issn | 0363-9762 | - |
dc.identifier.uri | http://hdl.handle.net/10722/344907 | - |
dc.description.abstract | Purpose The aim of this study was to identify and evaluate the role of 68Ga-DOTA-somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on the ability of PET/CT to impact clinical management and predict peptide receptor radionuclide therapy (PRRT) response. Patients and Methods A systematic literature search of articles up to December 2021 was performed using PubMed and Scopus. Eligible studies included ≥10 patients with confirmed or suspected NETs who had undergone pretreatment staging 68Ga-DOTA-SSA PET/CT. A meta-analysis using the random-effects model was conducted to determine the overall change in management after PET/CT, whereas PET/CT-derived parameters that correlated with PRRT outcome were summarized from studies that assessed its predictive capabilities. Results A total of 39 studies were included in this systemic review, of which 2266 patients from 24 studies were included for meta-analysis. We showed that PET/CT resulted in a change in clinical management in 36% (95% confidence interval, 31%-41%; range, 3%-66%) of patients. Fifteen studies consisting of 618 patients examined the prognostic ability of 68Ga-DOTA-SSA PET/CT for PRRT. Of those, 8 studies identified a higher pretreatment SUV to favor PRRT, and 4 identified PET-based radiomic features for somatostatin receptor heterogeneity to be predictive of PRRT response. Conclusions Along with its diagnostic abilities, 68Ga-DOTA-SSA PET/CT can impact treatment decision-making and may predict PRRT response in patients with NETs. More robust studies should be conducted to better elucidate the prognostic role of somatostatin receptor PET/CT in optimizing treatment for clinical outcome. | - |
dc.language | eng | - |
dc.publisher | Lippincott, Williams & Wilkins | - |
dc.relation.ispartof | Clinical Nuclear Medicine | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | 68Ga | - |
dc.subject | DOTA | - |
dc.subject | management | - |
dc.subject | neuroendocrine tumors | - |
dc.subject | peptide receptor radionuclide therapy | - |
dc.subject | PET/CT | - |
dc.title | The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/RLU.0000000000004235 | - |
dc.identifier.pmid | 35485851 | - |
dc.identifier.scopus | eid_2-s2.0-85135599157 | - |
dc.identifier.volume | 47 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 781 | - |
dc.identifier.epage | 793 | - |
dc.identifier.eissn | 1536-0229 | - |
dc.identifier.issnl | 0363-9762 | - |